

POSTER PRESENTATION

Open Access

Comparative immunohistochemical analysis of Beclin-1 & MDM-2 in benign & malignant ameloblastomas

MA Elbarrawy

From 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015)

National Harbor, MD, USA. 4-8 November 2015

Background

Ameloblastoma is the most frequently encountered neoplasm arising from the odontogenic epithelium. Beclin-1 protein plays a critical role in autophagy as a tumor suppressor gene. Whereas, the Murine Double Minute 2 (MDM-2) is a cellular proto-oncogene capable, if amplified, of causing tumor-genesis. The expression & prognostic significance of both genes are largely unexplored, yet, in this neoplasia. Therefore, the present investigation aimed to assess their possible biological role in ameloblastomas.

Methods

This study was done among 35 studied cases: 29 cases of benign ameloblastomas, and 6 cases of ameloblastic carcinomas. Labeled Streptavidin Biotin (LSAB + Dako) immunohistochemical method, utilizing monoclonal antibodies for Beclin-1 & MDM-2 genes, was used.

Results

Most of the benign ameloblastomas, 25 out of 29 cases (86%), showed intense total cell positivity for the Beclin-1, while, the ameloblastic carcinomas revealed mild (3 out of 6 cases, 50%) to negative expression (3 cases: 50%). Inversely, the MDM-2 oncoprotein demonstrated intense brown total cell reactivity in ameloblastic carcinoma (5 out of 6 cases, 83% positivity) & loss of the reaction (21 cases: 72%) to mild brown stain (8 cases:28%) in benign ameloblastoma. These findings were statistically significant.

Conclusion

Based from these findings, one could conclude that, MDM-2 could be a specific marker to identify the

proliferative activity, tumor aggressiveness & directly proportional with the degree of malignancy. In contrast, the high Beclin-1 expression could be a good indicator of prognosis in ameloblastomas. Hence, an overall comparison, both studied genes may be very promising molecular prognostic biomarkers.

Published: 4 November 2015

doi:10.1186/2051-1426-3-S2-P101

Cite this article as: Elbarrawy: Comparative immunohistochemical analysis of Beclin-1 & MDM-2 in benign & malignant ameloblastomas. *Journal for ImmunoTherapy of Cancer* 2015 **3**(Suppl 2):P101.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit



Alexandria University Egypt, Alexandria, Egypt



© 2015 Elbarrawy This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated.